Bellomo Giovanni, Indaco Antonio, Chiasserini Davide, Maderna Emanuela, Paolini Paoletti Federico, Gaetani Lorenzo, Paciotti Silvia, Petricciuolo Maya, Tagliavini Fabrizio, Giaccone Giorgio, Parnetti Lucilla, Di Fede Giuseppe
Laboratory of Clinical Neurochemistry, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Neurology 5/Neuropathology Unit, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy.
Front Neurosci. 2021 Mar 31;15:647783. doi: 10.3389/fnins.2021.647783. eCollection 2021.
Amyloid-beta (Aβ) 42/40 ratio, tau phosphorylated at threonine-181 (p-tau), and total-tau (t-tau) are considered core biomarkers for the diagnosis of Alzheimer's disease (AD). The use of fully automated biomarker assays has been shown to reduce the intra- and inter-laboratory variability, which is a critical factor when defining cut-off values. The calculation of cut-off values is often influenced by the composition of AD and control groups. Indeed, the clinically defined AD group may include patients affected by other forms of dementia, while the control group is often very heterogeneous due to the inclusion of subjects diagnosed with other neurological diseases (OND). In this context, unsupervised machine learning approaches may overcome these issues providing unbiased cut-off values and data-driven patient stratification according to the sole distribution of biomarkers. In this work, we took advantage of the reproducibility of automated determination of the CSF core AD biomarkers to compare two large cohorts of patients diagnosed with different neurological disorders and enrolled in two centers with established expertise in AD biomarkers. We applied an unsupervised Gaussian mixture model clustering algorithm and found that our large series of patients could be classified in six clusters according to their CSF biomarker profile, some presenting a typical AD-like profile and some a non-AD profile. By considering the frequencies of clinically defined OND and AD subjects in clusters, we subsequently computed cluster-based cut-off values for Aβ42/Aβ40, p-tau, and t-tau. This approach promises to be useful for large-scale biomarker studies aimed at providing efficient biochemical phenotyping of neurological diseases.
淀粉样蛋白β(Aβ)42/40比率、苏氨酸-181磷酸化tau蛋白(p-tau)和总tau蛋白(t-tau)被视为诊断阿尔茨海默病(AD)的核心生物标志物。已证明使用全自动生物标志物检测可减少实验室内和实验室间的变异性,这在定义临界值时是一个关键因素。临界值的计算通常受AD组和对照组组成的影响。实际上,临床定义的AD组可能包括受其他形式痴呆影响的患者,而对照组由于纳入了被诊断患有其他神经系统疾病(OND)的受试者,往往非常异质。在这种情况下,无监督机器学习方法可能会克服这些问题,根据生物标志物的唯一分布提供无偏临界值和数据驱动的患者分层。在这项工作中,我们利用脑脊液(CSF)核心AD生物标志物自动测定的可重复性,比较了两个被诊断患有不同神经系统疾病且在两个具有AD生物标志物既定专业知识的中心登记的大型患者队列。我们应用了无监督高斯混合模型聚类算法,发现我们的大量患者可根据其CSF生物标志物谱分为六个簇,一些呈现典型的AD样谱,一些呈现非AD谱。通过考虑簇中临床定义的OND和AD受试者的频率,我们随后计算了Aβ42/Aβ40、p-tau和t-tau基于簇的临界值。这种方法有望对旨在提供神经系统疾病有效生化表型的大规模生物标志物研究有用。